Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 500-315-8 | CAS number: 127087-87-0 1 - 2.5 moles ethoxylated
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu./o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- October 20 - November 20, 1997 to January 30, 1998
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
- Justification for type of information:
- Data is from NTRL report
Data source
Reference
- Reference Type:
- other: NTRL
- Title:
- SUPPORT: FINAL REPORT, DEVELOPMENTAL TOXICITY EVALUATION OF TERGITOL NP-4 SURFACTANT ADMINISTERED BY GAVAGE TO CD(SPRAGUE-DAWLEY) RATS, WITH COVER LETTER DATED 4/23/1999
- Author:
- Rochelle W. Tyl, Ph.D., DABT Melissa C. Marr, B.A., LATG Christina B. Myers, M.S.
- Year:
- 1 999
- Bibliographic source:
- UNION CARBIDE CORP, NTRL: OTS0559310-1, 1999
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: Refer below principle
- Principles of method if other than guideline:
- Repeated dose oral toxicity of the substance TERGITOL NP-4 was assesed in CD Sprague–Dawley rats.
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- 4-Nonylphenol, branched, ethoxylated
- EC Number:
- 500-315-8
- EC Name:
- 4-Nonylphenol, branched, ethoxylated
- Cas Number:
- 127087-87-0
- Molecular formula:
- C25H44O6
- IUPAC Name:
- 2-{2-[2-(4-nonylphenoxy)ethoxy]ethoxy}ethan-1-ol
- Test material form:
- liquid
- Details on test material:
- - Name of test material (as cited in study report): 4-Nonylphenol, branched, ethoxylated
- Molecular formula : C17H28O2
- Molecular weight : 264.409 g/mol
- Substance type:Organic
- Physical state: Liquid
Constituent 1
- Specific details on test material used for the study:
- - Name of test material : TERGITOL NP-4
- EC name: 4-Nonylphenol, branched, ethoxylated
- Molecular formula : C23H40O5 (SAX)
- Molecular weight : 396.63 g/mol (SAX)
- Substance type: Organic
- Physical state: Transparent, colourless Liquid
- Purity: > 97%
- Impurities (identity and concentrations): polyethylene glycol, <3%, dinonylphenol ethoxylate, <3%,
Test animals
- Species:
- rat
- Strain:
- other: CD (Sprague Dawley)
- Details on species / strain selection:
- No data
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Inc., Raleigh, NC.
- Age at study initiation:
Female rats= 56 days
Male rats= 70 days
- Weight at study initiation: No data available
- Fasting period before study: No data available
- Housing: Males were housed singly in solid-bottom polycarbonate cages (8" x 19" x 10.5") with stainless steel wire lids. Non mated females were group housed (maximum three per cage), and mated females were singly housed in solid-bottom polycarbonate cages (8" x 19" x 10.5") with stainless steel wire lids (Laboratory Products, Rochelle Park, NJ). Sani-Chips® animal bedding (P. J. Murphy Forest Products, Montville, NJ) was used in all cages.
- Diet (e.g. ad libitum): Pelleted feed (No. 5002 Purina Certified Rodent Diet®; PMI Feeds, Inc., St. Louis, MO). ad libitum
- Water (e.g. ad libitum): tap water (Durham, NC water system, in plastic bottles with stainless steel sipper tubes) available ad libitum
- Acclimation period: 7 days quarantine periods for the females
ENVIRONMENTAL CONDITIONS
- Temperature (°C):
target temp: 64-79°F (17.8 - 26.1°C)
maintained temp: 70.7-73.2°F (21.5 - 22.9 °C)
- Humidity (%):
target humidity: 30-70%
maintained humidity 35.7 - 63.8%
- Air changes (per hr): No data
- Photoperiod (hrs dark / hrs light): 12:12 hour light: dark cycle
IN-LIFE DATES:
From: Dosing: November 3-15,1997 (gestation day 6 through 15)
To: Necropsy: November 17-20,1997 (gestation day 20)
Administration / exposure
- Route of administration:
- oral: gavage
- Details on route of administration:
- No data
- Vehicle:
- corn oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS: The Tergitol NP-4 Surfactant for each dose was weighed out into a calibrated beaker (400 ml beaker to hold 200 ml, with adjustments for different volumes if needed). The appropriate volume of corn oil was added to each beaker, stirred with a stirring bar until the chemical was no longer visible, and then stirred for ten minutes more to give a dose range of 0, 50, 250 or 500 mg/Kg/day. The resulting formulation was sampled for archive and analytical samples and stored at 1-8°C in sealed, amber glass bottles protected from light. After storage and prior to use, the solutions were allowed to warm to room temperature and then stirred for ten minutes with a stirring bar. The formulations were then used for dosing.
DIET PREPARATION
- Rate of preparation of diet (frequency): No data
- Mixing appropriate amounts with (Type of food): No data
- Storage temperature of food: No data
VEHICLE
- Justification for use and choice of vehicle (if other than water): Corn oil
- Concentration in vehicle: 0, 50, 250 or 500 mg/Kg/day
- Amount of vehicle (if gavage): 1.0 ml/kg
- Lot/batch no. (if required): 325A7
- Purity: No data - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Prior to study dose formulation, formulations encompassing the range of dose employed (50 and 600 mg/mL) were assayed for homogeneity, stability, and dose level verification
- Duration of treatment / exposure:
- 10 consecutive days (Gestation day 6 through gestation day 15)
- Frequency of treatment:
- Once daily
Doses / concentrations
- Remarks:
- 0, 50, 250, or 500 mg/kg/day
- No. of animals per sex per dose:
- Total: 100
0 mg/kg/day=25 sperm positive females
50 mg/kg/day=25 sperm positive females
250 mg/kg/day=25 sperm positive females
500 mg/kg/day=25 sperm positive females - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Doses was based on a range-finding study in pregnant rats performed at RTI. In range finding study, four group of eight sperm positive females were dosed once daily on gestation day 6 through 15 at concentartion 0, 500, 1500, and 3000 mg/kg/day at a dosing volume of 5.0 ml/kg. At 1500 and 3000 mg/kg/day, at least 50% of the dams died. At 500 mg/kg/day, all dams survived and were pregnant; seven of eight dams were pregnant at 0 mg/kg/day. Therefore, the highest dose level for the present study, 500 mg/kg/day, was chosen to induce overt maternal and developmental toxicity.
- Rationale for animal assignment (if not random): Sperm-positive female rats (dams) were assigned to treatment groups by a stratified randomization method, designed to provide uniform mean body weights across dose groups on gd 0 at the initiation ofthe study.
- Rationale for selecting satellite groups: No data available
- Post-exposure recovery period in satellite groups: No data available
- Section schedule rationale (if not random): No data available - Positive control:
- No data
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: once daily
- Cage side observations checked in table [No.?] were included.
DETAILED CLINICAL OBSERVATIONS: yes
- Time schedule: daily, except during the dosing period when they were made at least twice daily. At least once daily on gd 0-5 (prior to dosing period), on gd 16-20 (postdosing period) at least twice daily, at dosing, and at least once after dosing throughout the dosing period (gd 6 through gd 15).
BODY WEIGHT: Yes
- Time schedule for examinations: Maternal body weights were taken on gestational day 0, 6,9,12,15,18, and 20
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes, measured for the intervals gestational day 0-6, 6-9, 9-12, 12-15, 15-18, 18-20, 6-15 (treatment period), 15-20 (posttreatment period), and 0-20 (gestational period)..
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: No data
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No data
FOOD EFFICIENCY: No data
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No data
- Time schedule for examinations: No data
OPHTHALMOSCOPIC EXAMINATION: No data
- Time schedule for examinations: No data
- Dose groups that were examined: No data
HAEMATOLOGY: No data
- Time schedule for collection of blood: No data
- Anaesthetic used for blood collection: No data
- Animals fasted: No data
- How many animals: No data
- Parameters checked in table [No.?] were examined. No data
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: No data
- Animals fasted: No data
- How many animals: No data
- Parameters checked in table [No.?] were examined. No data
URINALYSIS: No data
- Time schedule for collection of urine: No data
- Metabolism cages used for collection of urine: No data
- Animals fasted: No data
- Parameters checked in table [No.?] were examined. No data
NEUROBEHAVIOURAL EXAMINATION: No data
- Time schedule for examinations: No data
- Dose groups that were examined: No data
- Battery of functions tested: sensory activity / grip strength / motor activity / other: No data
OTHER: - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes, On gd 20, maternal animals were sacrificed by asphyxiation with C02, thoracic and abdominal cavities and organs examined, and their pregnancy status was confirmed by uterine examination. At sacrifice, the body, liver, and uterus of each sperm-positive female were weighed, ovarian corpora lutea counted, and uterine contents (i.e., number of implantation sites, resorptions, dead fetuses, live fetuses) recorded.
HISTOPATHOLOGY: No data available - Other examinations:
- Uteri which presented no visible implantation sites were stained with ammonium sulfide (10%) in order to visualize any implantation sites, which may have undergone very early resorption. All live fetuses were weighed, sexed, and examined for external morphological abnormalities, inclUding cleft palate. Approximately one-half of the live fetuses per litter were examined for visceral abnormalities and had their sex confirmed using a fresh tissue dissection method. These fetuses were decapitated prior to dissection, and the heads were fixed in Bouin's solution for free-hand sectioning and examination. All fetal carcasses were eviscerated, macerated, and stained with alcian blue/alizarin red S, and half (intact fetuses) per litter were examined for skeletal malformations and variations. After examination, all maternal and fetal organs and maternal carcasses were destroyed by incineration. Fetal carcasses were stored in glycerin:70% ethanol (1:1) following examination of skeletal structures or for those not examined skeletally; fetal heads were stored in 70% ethanol solution.
- Statistics:
- As mentioned below
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, non-treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Gross pathological findings:
- effects observed, treatment-related
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- not specified
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- effects observed, treatment-related
- Details on results:
- Clinical signs and mortality:
Mortality: One female at 500 mg/kg/day died on gd 6 after dosing sue to misdirected dose
Clinical signs: Treatment-related clinical observations were present almost exclusively at 250 and 500 mg/kg/day. Rust colored fur on the head, face, and back, a nonspecific indicator of stress (from hemoglobin breakdown products in the Harderian gland excreted via the tear ducts, so-called "bloody tears" or chromodacryorrhea, groomed from the eyes and nose), was observed only at 500 mg/kg/day and only on gd 13 and 15. Piloerection, another nonspecific sign of stress, was observed at 500 mg/kg/day on gd 6 through 20, at 250 mg/kg/day on gd 7-10 and 13-15, and at 50 mglkg/day on gd 14 in one dam, in dose-related patterns of incidence and time to presence. Rough coat (more severe than piloerection, indicative of more stress) was observed only at 500 mg/kg/day on gd 12-15. Rooting in bedding postdosing (most likely due to taste aversion and not toxicity, per se) was observed at all doses on gd 7-15 in a dose-related pattern of incidence. Lethargy bwas observed at 500 mg/kg/day on gd 6-15 and at 250 mg/kg/dayon gd 7 (one dam) and 8 (one dam).
Prone positioning was observed only at 500 mg/kg/day on gd 6-14. Pica was observed at 250 mg/kg/day on gd 6 and 8 and at 500 mg/kg/day on gd 6 and 7. Other clinical observations, such as alopecia (various areas), were unrelated to treatment.
Body weight and weight gain: Maternal body weights were equivalent across all groups for gd 0 and 6 prior to the onset of dosing. Starting on gd 9, mean body weights at 250 and 500 mg/kg/day were statistically significantly reduced for gd 9, 12, 15, and 18. Maternal body weights on gd 20 (in-life and at sacrifice) were unaffected. Maternal weight change was equivalent across all groups for gd 0-6, prior to the onset of dosing. Maternal weight change was significantly reduced at all doses for gd 6-9, the first interval of the dosing period, and was significantly reduced at 500 mg/kg/day for gd 9-12. Maternal weight change for the treatment period (gd 6-15) was significantly reduced at 250 and 500 mg/kg/day. Maternal weight changes were significantly increased at 250 and 500 mg/kg/day for gd 15-18 and 18-20 during the postdosing period. Weight change during the entire postdosing period (gd 15-20) was also significantly increased at 250 and 500 mg/kg/day. Maternal gestational weight change and gestational weight change corrected for the weight of the gravid uterus were unaffected.
Food consumption and compound intake: Feed consumption was statistically significantly reduced at 250 and 500 mg/kg/day for gestation day 6-15 (treatment period), and 0-20 (gestational period). And was significantly increased for gestation day 18-20 at all doses. Maternal feed consumption as g/kgfday was significantly increased at 500 mg/kg/day for gd 18-20 and 15-20 (postdosing period), at 250 mg/kg/day for gd 18-20 and 15-20, and at 50 mg/kgfday for gd 18-20 and 15-20
Food efficiency: No data available
Water consumption and compound intake: No data available
Opthalmoscopic examination: No data available
Haematology: No data available
Clinical chemistry: No data available
Urinanalysis: No data available
Neurobehaviour: No data available
Organ weights: Absolute liver weight and maternal liver weight, relative to terminal body weight, were significantly increased at all doses. However, this finding may be due to induction of hepatic metabolizing enzymes and concomitant increase in liver mass and not to toxicityGravid uterine weight was unaffected.
Gross pathology: Necropsy findings for unscheduled deaths (one at 500 mg/kg/day) included blood present in urogenital opening, urinary bladder, mouth and nose, and lung lobes hemorrhagic and edematous. At scheduled necropsy on gd 20, one dam at 50 mg/kg/day exhibited an area of extra hard tissue on left median liver lobe.
Histopathology: No data available
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 50 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: No significant alterations were observed
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Table: Summary and Statistical Analysis of Matemal Body Weights, Weight Changes, Organ Weights and Relative Organ Weights
|
Tergitol (mg/kg/day, po) |
|||
|
0 |
50 |
250 |
500 |
No. of animals |
25 |
25 |
25 |
25 |
No. of Removed |
0 |
1a |
0 |
0 |
No. found dead |
0 |
0 |
0 |
1b |
Maternal body weight (gd 0) (g) |
227.6 ± 2.3 |
226.9±2.2 |
227.0± 2.3 |
228.7±2.4 |
Maternal body weight (gd 20 at sacrifice) (g) |
365.4±3.3 |
370.2±4.4 |
365.5±3.1 |
358.1±4.2 |
Gravid Uterine weight (g) |
82.54±1.86 |
82.30±2.44 |
85.54±2.40 |
82.99±2.96 |
Maternal Liver weight (g) |
15.93±0.21 |
16.69±0.25** |
16.74±0.21* |
17.16±0.25** |
Relative Maternal Liver weight (g) |
4.36±0.04 |
4.58±0.04 |
4.58±0.04 |
4.80±0.07 |
Maternal feed consumtion (gd 0-6) (g/day) |
22.2±05 |
23.0±0.5 |
22.3±0.5 |
22.9±0.5 |
Maternal feed consumtion (gd 0-20) (g/kg/day) |
77.8±0.7 |
80.1±0.7 |
75.4±1.0 |
72.7±0.9** |
aDam 98 was removed because she delivered on gestational day 19
bDam 63 was found dead on gestational day 6 after dosing
*p<0.05 Dunnett's Test
**p<0.01 Dunnett's Test
Applicant's summary and conclusion
- Conclusions:
- The No Observed Adverse Effect Level (NOAEL) for TERGITOL NP-4 is considered to be 50 mg/kg/day in CD Sprague–Dawley rats.
- Executive summary:
Repeated dose oral toxicity study for substanceTERGITOL NP-4 (EC name: 4-Nonylphenol, branched, ethoxylated) was conducted intimed-pregnant CD (Sprague-Dawley) rats. Based on the range finding study dose were selected. Tergitol NP-4 Surfactant, dissolved in corn oil and administered by gavage once daily on gestational days (gd) 6 through 15, to 4 group of 25 sperm-positive at doses of 0,50, 250, or 500 mg/kg/day at a dosing volume of 1.0 ml/kg. The rats were observed for mortality, clincal signs, body weight and feed consumption changes, gross pathology and organ weight changes. One pregnant female rat died at 500 mg/kg/day. Maternal body weights were significantly reduced at all doses and body weight gain were significantly reduced at 250 and 500 mg/kg/day and No effect observed on gestational weight gain, corrected for gravid uterine weight, and gravid uterine weight. Increased absolute and relative liver weight was observed. However, this finding may be due to induction of hepatic metabolizing enzymes and concomitant increase in liver mass and not to toxicity. Maternal treatment-related clinical signs were observed at 250 and 500 mg/kg/day. Maternal feed consumption was significantly reduced at 250 and 500 mg/kg/day and was significantly increased at all doses for gd 18-20. Fetal related observations like increased incidences of fetal skeletal variations, specifically bilateral and unilateral rudimentary ribs on Lumbar I increased at 250 and 500 mgl1<g/day, and normal cartilage, bipartite ossification center in a thoracic centrum apparently increased at 500 mg/kg/day, with no statistically significant difference. The incidence of fetal cleft palate was also observed but was not statistically significantly different among groups. These findings were observed in the absence of any treatment-related effects on pre or postimplantation loss, live litter size, sex ratio (% males), or on fetal body weight per litter. The No Observed Adverse Effect Level (NOAEL) for TERGITOL NP-4 is considered to be 50 mg/kg/day in CD Sprague–Dawley rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)